Loading…
Runs an e-commerce catalog selling laboratory reagents and fine chemicals to Chinese research labs.
Runs an e-commerce catalog selling laboratory reagents and fine chemicals to Chinese research labs.
Sells a very broad catalogue of reagents and chemicals through its website and marketplaces, with quick delivery to research labs, so orders are small but frequent and rely on repeat buyers. Products are a mix of items it makes itself and others it resells, and the own-made items carry better margins.
In one line: A Chinese Sigma-Aldrich (lab reagent catalog/e-commerce).
Moat: narrow (distribution, brand, installed base). Broad reagent catalog and e-commerce platform create convenience-driven repeat buying.
Headquarters: Shanghai, China · Founded: 2009 · Employees: 926
Size Shanghai Aladdin Biochemical Technology (688179.SS) is a China Health Care company (Medical Specialties) with a market value of $806M, the 2741st largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥14.82 on 6 Nov 2026.
Performance Over six months the shares fell 24.9%, against -7.2% for the median peer and -16.4% for the China market (cap-weighted) — 5th lowest of 21 in its peer set.
Growth Revenue grew 38.8% over the last twelve months (peer median +10.0%); the operating margin is 25.8% (peer median 9.6%).
Valuation It trades at 30.0× forward earnings against a peer median of 19.8× (3rd most expensive of 14).
Price implies For today's price to make sense, revenue must grow about 21% a year for seven years (Req g). Recent delivered growth is +24%, so the hurdle is -3 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 0.4 points below its cost of capital (10.4% WACC).
Next results Next results expected around 21 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥789M | CN¥690M | CN¥530M | CN¥402M | CN¥377M |
| Revenue growth | — | +30% | +32% | +7% | — |
| Gross profit | CN¥476M | CN¥405M | CN¥305M | CN¥216M | CN¥202M |
| EBITDA | CN¥253M | CN¥215M | CN¥170M | CN¥118M | CN¥115M |
| Net income | CN¥142M | CN¥102M | CN¥98.8M | CN¥85.8M | CN¥92.8M |
| Free cash flow | CN¥212M | CN¥356M | CN¥117M | CN¥10.1M | -CN¥105M |
| Capital expenditure | CN¥29.5M | CN¥49.0M | CN¥35.5M | CN¥45.7M | CN¥62.0M |
| Total debt | CN¥473M | CN¥773M | CN¥443M | CN¥358M | CN¥342M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Shanghai Aladdin Biochemical Technology 688179.SS | $806M | -25% | +39% | 26% | 30.0× | 21.1% |
| Merck KGaA MRK.DE | $72.5B | +23% | 0% | 20% | 17.5× | 7.7% |
| Bide Pharmatech 688073.SS | $912M | +5% | +10% | 19% | 27.5× | 16.7% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 688179.SS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -26.4% | -2.5% | 2nd lowest of 21 |
| 6-month return | -24.9% | -7.2% | 5th lowest of 21 |
| Distance from 52-week high | -53.1% | -30.2% | 2nd lowest of 21 |
| Revenue growth (TTM) | +38.8% | +10.0% | 4th highest of 21 |
| Operating margin | 25.8% | 9.6% | highest of 21 |
| Forward P/E | 30.0× | 19.8× | 3rd most expensive of 14 |
| Growth the price implies (Req g, 7 yrs) | 21.1% | 0.1% | 2nd most demanding of 12 |
| Growth delivered (Del g) | +24.2% | +15.6% | 2nd highest of 12 |
| Hurdle (Req g minus delivered) | -3.1 pp | -18.0 pp | 4th most demanding of 12 |
| ROIC minus cost of capital | -0.4 pp | +0.8 pp | 10th lowest of 21 |
| EV / EBITDA | 21.1× | 13.2× | 2nd most expensive of 10 |
| Net debt / EBITDA | -1.0× | -0.0× | 5th least indebted of 11 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai Aladdin Biochemical Technology 688179.SS | China | $806M | -25% | +39% | 26% | 30.0× | 21.1% | +24.2% |
| Maccura Biotechnology 300463.SZ | China | $814M | -14% | -1% | -4% | 164.7× | 9.2% | -10.2% |
| Allmed Medical Products 002950.SZ | China | $798M | -39% | +14% | 8% | n/a | n/a | n/a |
| Cofoe Medical Technology 1187.HK | Hong Kong | $798M | -27% | +40% | 10% | 12.5× | -8.0% | +6.6% |
| Standard Engineering Technology SETL.NS | India | $796M | +164% | +26% | 13% | n/a | n/a | n/a |
| Advanced Medical Solutions AMS.L | United Kingdom | $824M | +14% | +6% | 12% | 20.7× | 19.6% | +21.4% |
| Hangzhou Biotest Biotech 688767.SS | China | $824M | +5% | -4% | 3% | 34.7× | n/a | n/a |
| Shanghai INT Medical Instruments 1501.HK | Hong Kong | $784M | -25% | +35% | 21% | 17.8× | -2.1% | +23.5% |
| OrthoPediatrics KIDS | United States | $829M | +78% | +16% | -8% | n/a | n/a | n/a |
| Varex Imaging VREX | United States | $783M | -10% | +5% | 8% | 20.3× | n/a | n/a |
| Beijing Aerospace Changfeng 600855.SS | China | $832M | -35% | -10% | -19% | n/a | n/a | n/a |
| BMC Medical 301367.SZ | China | $780M | -13% | +37% | 17% | 19.8× | 0.1% | +15.6% |
| InMode INMD | United States | $767M | -5% | -7% | 18% | 10.1× | -10.5% | +12.4% |
| Zylox-Tonbridge Medical Technology 2190.HK | Hong Kong | $851M | -13% | +39% | 25% | 15.9× | 5.5% | +105.8% |
| Beta Bionics BBNX | United States | $854M | +63% | +44% | -73% | n/a | n/a | n/a |
| Menicon 7780.T | Japan | $854M | +12% | +5% | 9% | 19.3× | n/a | n/a |
| Cytek Biosciences CTKB | United States | $758M | +26% | +5% | -22% | n/a | n/a | n/a |
| Doctorglasses Chain 300622.SZ | China | $757M | -10% | +6% | 14% | 24.5× | -2.4% | +15.7% |
| MedCap MCAP.ST | Sweden | $864M | +6% | +17% | 15% | 26.4× | 2.9% | +20.9% |
| JINS 3046.T | Japan | $865M | -12% | +14% | 10% | 16.6× | -7.2% | +11.7% |
| Anhui Hongyu Wuzhou Medical Manufacturer 301234.SZ | China | $750M | +177% | -14% | 3% | n/a | 33.5% | -0.6% |